SG10201600077RA - Combination - Google Patents

Combination

Info

Publication number
SG10201600077RA
SG10201600077RA SG10201600077RA SG10201600077RA SG10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA
Authority
SG
Singapore
Prior art keywords
combination
Prior art date
Application number
SG10201600077RA
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SG10201600077RA publication Critical patent/SG10201600077RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201600077RA 2011-01-11 2012-01-11 Combination SG10201600077RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11

Publications (1)

Publication Number Publication Date
SG10201600077RA true SG10201600077RA (en) 2016-02-26

Family

ID=46507420

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201600077RA SG10201600077RA (en) 2011-01-11 2012-01-11 Combination
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (enExample)
EP (1) EP2663189B1 (enExample)
JP (1) JP6100700B2 (enExample)
KR (1) KR20140053836A (enExample)
CN (1) CN103298345B (enExample)
AU (1) AU2012205601B2 (enExample)
BR (1) BR112013017722A2 (enExample)
CA (1) CA2824201A1 (enExample)
EA (1) EA029000B1 (enExample)
ES (1) ES2689760T3 (enExample)
IL (1) IL227097B (enExample)
MX (1) MX356704B (enExample)
SG (2) SG10201600077RA (enExample)
WO (1) WO2012097021A1 (enExample)
ZA (1) ZA201304139B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806266A (zh) * 2013-10-01 2019-05-28 诺华股份有限公司 用于癌症治疗的组合及其应用
JP6568093B2 (ja) * 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ,エルエルシー ガンの処置に有用なtie2キナーゼの阻害方法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
EP1740579B1 (en) * 2004-03-24 2015-08-19 AbbVie Inc. Tricyclic pyrazole kinase inhibitors
KR100872675B1 (ko) 2004-10-13 2008-12-10 파마시아 앤드 업존 캄파니 엘엘씨 3-[5-클로로-4-[(2,4-디플루오로벤질)옥시]-6-옥소피리미딘-1(6h)-일]-n-(2-히드록시에틸)-4-메틸벤즈아미드의결정형
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP2275095A3 (en) * 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
KR20080108516A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
PL2478907T3 (pl) 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
CL2007002948A1 (es) 2006-10-13 2008-05-30 Basf Ag Hidratos del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluor-n-((metil(1-metiletil)amino)sulfonil]benzamida; proceso para la preparacion de dicho hidrato; composicion fitoprotectora; y metodo para con
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
CN102405047B (zh) 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
MX2012004140A (es) 2009-10-08 2012-09-07 Glaxosmithkline Llc Combinacion.
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
AU2012250650A1 (en) 2011-05-03 2013-11-14 University Of Rochester Methods for treating prostate cancer
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス,インク. Bruton型チロシンキナーゼの阻害剤
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
MX2016004265A (es) 2013-10-01 2016-07-08 Novartis Ag Combinacion.

Also Published As

Publication number Publication date
US20120258933A1 (en) 2012-10-11
IL227097B (en) 2018-02-28
BR112013017722A2 (pt) 2016-07-12
EP2663189B1 (en) 2018-07-04
SG191724A1 (en) 2013-08-30
CA2824201A1 (en) 2012-07-19
CN103298345B (zh) 2016-12-14
US20160022641A1 (en) 2016-01-28
MX356704B (es) 2018-06-11
ZA201304139B (en) 2014-02-26
AU2012205601A1 (en) 2013-08-01
WO2012097021A1 (en) 2012-07-19
MX2013008074A (es) 2013-08-09
ES2689760T3 (es) 2018-11-15
EP2663189A4 (en) 2014-06-11
US20150119337A1 (en) 2015-04-30
EA029000B1 (ru) 2018-01-31
EA201391027A1 (ru) 2014-01-30
CN103298345A (zh) 2013-09-11
AU2012205601B2 (en) 2016-03-24
US10449226B2 (en) 2019-10-22
US20130288984A1 (en) 2013-10-31
JP2014507412A (ja) 2014-03-27
KR20140053836A (ko) 2014-05-08
US20170100449A1 (en) 2017-04-13
US20160375086A1 (en) 2016-12-29
EP2663189A1 (en) 2013-11-20
JP6100700B2 (ja) 2017-03-22

Similar Documents

Publication Publication Date Title
DK3798230T3 (en) Terapeutiske antistoffer
AP2014007621A0 (en) 2-Thiopyrimidinones
ZA201304866B (en) Colonoscopy-preparation
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
SG10201606981QA (en) 18f-saccharide-folates
GB201109820D0 (en) GeoROV
GB201121105D0 (en) Combination
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201112272D0 (en) Nevadrop pickstrap
GB201117435D0 (en) Ergonomibus
GB201100055D0 (en) Evac-sac
GB201100364D0 (en) Aimspray
GB201112142D0 (en) Zogo24
GB201101931D0 (en) Kerbknight
GB201102519D0 (en) Mirrorcane
GB201102755D0 (en) Protectaridge
GB201102977D0 (en) Cyclobuggy
GB201104258D0 (en) BallOnT
GB201104492D0 (en) Magna-spin
GB201104723D0 (en) Thermo-symbiotic-gaming
AU338420S (en) Kettlebell
GB201101143D0 (en) Post-reference